HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Divulges Cosmetics Enforcement Data, Notes Hair Loss As ‘Serious’ AE

This article was originally published in The Rose Sheet

Executive Summary

Momentum this year behind legislative proposals for cosmetics regulatory reform has prompted key Congress members to question FDA about the current oversight system. In a response to the Senate HELP Committee’s chairman, FDA provides a wealth of data on its enforcement activities and confirms hair loss as an adverse event it considers “serious,” if not one currently identified as such by MedWatch’s definition.

You may also be interested in...



Diamond Wipes’ FDA Headaches Suggest Cosmetic Recall Hangover

Following an FDA warning letter in 2016 for an unapproved sunscreen drug product, Diamond Wipes now must answer agency concerns regarding “poor-quality water” used in its manufacturing operations. Both warnings stemmed from inspections in the wake of a 2014 product recall for mold contamination.

ICMAD Clutches To House Cosmetics Bill Before Specter Of ‘Activist FDA’

Locke Lord attorney Sharon Blinkoff, general counsel for the small-business trade group, says the newly introduced Safe Cosmetics Modernization Act is crafted to update cosmetics regulations without making room for oppressive oversight or a revival of the aggressively conservative FDA of decades past.

Honest Recalls Baby Powder Due To Possible Contamination

The Honest Company recalls all lots of its Organic Baby Powder following routine testing that indicated potential contamination with unsavory microorganisms. FDA scrutiny could follow.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS108663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel